Sep 15, 2021 / 03:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Vertex with us for the next session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
So before we get into Q&A, I'm going to turn it over to Reshma to make some opening comments, and then we'll jump right into it.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Great. Hey, thanks, Matt, for the invitation to participate, and good morning all. I also will be making some statements because there are some risks and uncertainties that could impact the actual events of our business. I'll direct you to our SEC filings where this is all discussed
Vertex Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers